Imagerie moléculaire 175
38. Linden HM, Stekhova SA, Link JM, et al. l l (2006) Quantitative fluoroestradiol positron
emission tomography imaging predicts response to endocrine treatment in breast cancer. J
Clin Oncol 24(18): 2793-9
39. van Kruchten M, Glaudemans AW, de Vries EF, et al. (2012) PET imaging of estrogen
receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma.
J Nucl Med 53(2): 182-90
40. Dijkers EC, Kosterink JG, Rademaker AP, et al. l l (2009) Development and characterization
of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med
50(6): 974-81
41. Kramer-Marek G, Gijsen M, Kiesewetter DO, et al. l l (2012) Potential of PET to predict the
response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. J
Nucl Med 53(4): 629-37
42. Kenny LM, Coombes RC, Oulie I, et al. (2008) Phase I trial of the positron-emitting
l l
Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl
Med 49(6): 879-86
43. Sorace AG, Saini R, Mahoney M, Hoyt K (2012) Molecular ultrasound imaging using
a targeted contrast agent for assessing early tumor response to antiangiogenic therapy. J
Ultrasound Med 31(10): 1543-50
44. Conley SJ, Gheordunescu E, Kakarala P, et al. (2012) Antiangiogenic agents increase breast
l l
cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 109(8):
2784-9
45. Enfield LC, Gibson AP, Hebden JC, et al. (2009) Optical tomography of breast cancerl l
monitoring response to primary medical therapy. Target Oncol 4(3): 219-33
46. Shah C, Miller TW, Wyatt SK, et al. (2009) Imaging biomarkers predict response to
l l
anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res
15(14): 4712-21
47. Beekman CA, Buckle T, van Leeuwen AC, et al. (2011) Questioning the value of (99m)
l l
Tc-HYNIC-annexin V based response monitoring after docetaxel treatment in a mouse
model for hereditary breast cancer. Appl Radiat Isot 69(4): 656-62
38. Linden HM, Stekhova SA, Link JM, et al. l l (2006) Quantitative fluoroestradiol positron
emission tomography imaging predicts response to endocrine treatment in breast cancer. J
Clin Oncol 24(18): 2793-9
39. van Kruchten M, Glaudemans AW, de Vries EF, et al. (2012) PET imaging of estrogen
receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma.
J Nucl Med 53(2): 182-90
40. Dijkers EC, Kosterink JG, Rademaker AP, et al. l l (2009) Development and characterization
of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging. J Nucl Med
50(6): 974-81
41. Kramer-Marek G, Gijsen M, Kiesewetter DO, et al. l l (2012) Potential of PET to predict the
response to trastuzumab treatment in an ErbB2-positive human xenograft tumor model. J
Nucl Med 53(4): 629-37
42. Kenny LM, Coombes RC, Oulie I, et al. (2008) Phase I trial of the positron-emitting
l l
Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl
Med 49(6): 879-86
43. Sorace AG, Saini R, Mahoney M, Hoyt K (2012) Molecular ultrasound imaging using
a targeted contrast agent for assessing early tumor response to antiangiogenic therapy. J
Ultrasound Med 31(10): 1543-50
44. Conley SJ, Gheordunescu E, Kakarala P, et al. (2012) Antiangiogenic agents increase breast
l l
cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A 109(8):
2784-9
45. Enfield LC, Gibson AP, Hebden JC, et al. (2009) Optical tomography of breast cancerl l
monitoring response to primary medical therapy. Target Oncol 4(3): 219-33
46. Shah C, Miller TW, Wyatt SK, et al. (2009) Imaging biomarkers predict response to
l l
anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res
15(14): 4712-21
47. Beekman CA, Buckle T, van Leeuwen AC, et al. (2011) Questioning the value of (99m)
l l
Tc-HYNIC-annexin V based response monitoring after docetaxel treatment in a mouse
model for hereditary breast cancer. Appl Radiat Isot 69(4): 656-62
Précédent